CLINICAL_TRIALS
research
· 2023-03-01
Clinical Trial Update: Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol) [Phase 4]
Summary
Phase 4 trial investigating oral bismuth subsalicylate (Pepto-Bismol) for diarrhea in COVID-19 patients; study completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Cincinnati | Conditions: Diarrhea, COVID-19 | Phase 4 | Status: COMPLETED | Results posted: 2023-03-01